Infutraze (Zinc Chloride, Potassium Iodide, Sodium Selenite, Copper Chloride Dihydrate, Manganese Chloride Tetr)

Each element serves as a cofactor for specific enzymes: zinc supports DNA synthesis and immune function; iodine is required for thyroid hormone production; selenium is a component of antioxidant enzymes; copper participates in iron metabolism and connective‑tissue formation; manganese is needed for carbohydrate metabolism. Together they restore normal enzymatic activity and metabolic balance during intravenous feeding.

The dose of Infutraze is individualized by the prescribing clinician based on the patient’s age, weight, clinical condition and laboratory trace‑element levels. The healthcare professional determines the appropriate volume and infusion rate for each case.

Safety data for Infutraze in pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the Infutraze product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Infutraze provides a balanced combination of five essential trace elements in a single sterile solution, which can simplify formulation of total parenteral nutrition compared with using separate single‑element additives. Its EU‑origin manufacturing ensures compliance with stringent quality standards, offering consistent concentration and sterility.

Infutraze must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Before use, inspect the container for particulate matter or discoloration and allow the solution to reach room temperature if required by the infusion protocol.

Infutraze is administered intravenously, usually added to a compatible parenteral nutrition bag or infused separately according to the prescribing clinician’s instructions. The infusion rate and dilution are determined by the patient’s clinical status and the total nutrient regimen.

Serious risks include severe hypersensitivity reactions (anaphylaxis), significant electrolyte disturbances, copper or selenium toxicity with prolonged high‑dose exposure, hepatic dysfunction, and acute renal impairment in susceptible patients. Prompt recognition and discontinuation are essential if these events occur.

Infutraze should be avoided in patients with known hypersensitivity to any of its components, in those with severe hepatic or renal failure where trace‑element accumulation is a concern, and in individuals receiving incompatible intravenous solutions that could precipitate metal ions.